share_log

Moderna | 8-K: Current report

Moderna | 8-K: Current report

Moderna | 8-K：重大事件
美股SEC公告 ·  10/02 07:10
Moomoo AI 已提取核心訊息
On September 28, 2024, Moderna, Inc. announced the appointment of Abbas Hussain to its Board of Directors, effective October 2, 2024. Hussain, with over 35 years of experience in healthcare, including leadership roles at Vifor Pharma, GlaxoSmithKline, and Eli Lilly and Company, brings extensive expertise in global vaccine commercialization and pharmaceuticals. His appointment coincides with the expansion of the Board to nine directors. Hussain will serve as a Class II director until the 2026 annual meeting of shareholders. In addition to his board role, he will also join the Audit Committee. The appointment was made upon the recommendation of the Nominating and Corporate Governance Committee and was announced in a press release on October 2, 2024. Hussain's compensation aligns with the company's Non-Employee Director Compensation Policy. There are no reported arrangements, family relationships, or transactions between Hussain and other company personnel that would require disclosure under SEC regulations.
On September 28, 2024, Moderna, Inc. announced the appointment of Abbas Hussain to its Board of Directors, effective October 2, 2024. Hussain, with over 35 years of experience in healthcare, including leadership roles at Vifor Pharma, GlaxoSmithKline, and Eli Lilly and Company, brings extensive expertise in global vaccine commercialization and pharmaceuticals. His appointment coincides with the expansion of the Board to nine directors. Hussain will serve as a Class II director until the 2026 annual meeting of shareholders. In addition to his board role, he will also join the Audit Committee. The appointment was made upon the recommendation of the Nominating and Corporate Governance Committee and was announced in a press release on October 2, 2024. Hussain's compensation aligns with the company's Non-Employee Director Compensation Policy. There are no reported arrangements, family relationships, or transactions between Hussain and other company personnel that would require disclosure under SEC regulations.
2024年9月28日，Moderna, Inc.宣佈任命Abbas Hussain爲其董事會成員，任命自2024年10月2日起生效。Hussain在醫療保健領域擁有超過35年的經驗，包括曾在Vifor Pharma，葛蘭素史克和Eli Lilly and Company擔任領導職務，在全球生物-疫苗商業化和製藥方面具有廣泛的專業知識。他的任命是董事會擴展至九名董事的同時進行的。Hussain將擔任二類董事，任期至2026年股東年會。除了董事會職務外，他還將加入審計委員會。該任命是根據提名和公司治理委員會的推薦做出的，並於2024年10月2日的新聞稿中宣佈。Hussain的薪酬與公司的非僱員董事薪酬政策一致。根據SEC法規，Hussain與其他公司人員之間沒有報告的安排、家庭關係或交易需要披露。
2024年9月28日，Moderna, Inc.宣佈任命Abbas Hussain爲其董事會成員，任命自2024年10月2日起生效。Hussain在醫療保健領域擁有超過35年的經驗，包括曾在Vifor Pharma，葛蘭素史克和Eli Lilly and Company擔任領導職務，在全球生物-疫苗商業化和製藥方面具有廣泛的專業知識。他的任命是董事會擴展至九名董事的同時進行的。Hussain將擔任二類董事，任期至2026年股東年會。除了董事會職務外，他還將加入審計委員會。該任命是根據提名和公司治理委員會的推薦做出的，並於2024年10月2日的新聞稿中宣佈。Hussain的薪酬與公司的非僱員董事薪酬政策一致。根據SEC法規，Hussain與其他公司人員之間沒有報告的安排、家庭關係或交易需要披露。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息